Literature DB >> 23446149

TLR2 deletion promotes arthritis through reduction of IL-10.

Qi-Quan Huang1, Renee E Koessler, Robert Birkett, Harris Perlman, Lianping Xing, Richard M Pope.   

Abstract

RA is a chronic inflammatory disease characterized by the persistent expression of inflammatory cytokines from macrophages, which may be mediated, in part, through TLR2 signaling. Earlier studies demonstrate a role for TLR2 signaling in dampening the arthritis in IL-1Ra-/- mice, which was mediated through T cells. This study was performed to determine whether TLR2 signaling plays a role in the pathogenesis of T cell-independent arthritis triggered by transferring serum from K/BxN mice. We documented more severe arthritis in Tlr2-/- mice compared with WT controls. The Tlr2-/- mice also demonstrated increased inflammation, erosion, pannus formation, and osteoclastogenesis, as well as increased IL-1β and decreased IL-10 within the joints. In vitro bone marrow-differentiated macrophages expressed comparable levels of activating and inhibitory FcγRs, however when stimulated with immune complexes, the Tlr2-/- macrophages expressed decreased IL-10 and reduced activation of Akt and ERK. Our findings indicate that Tlr2-/- promotes the effector phase of arthritis through decreased IL-10 by macrophages, which is important, not only as an anti-inflammatory cytokine but also in restraining the differentiation and activation of osteoclasts.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23446149      PMCID: PMC3629443          DOI: 10.1189/jlb.0912473

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  69 in total

1.  Myeloid cell IL-10 production in response to leishmania involves inactivation of glycogen synthase kinase-3β downstream of phosphatidylinositol-3 kinase.

Authors:  Devki Nandan; Carolina Camargo de Oliveira; Alireza Moeenrezakhanlou; Martin Lopez; Judith M Silverman; Jennifer Subek; Neil E Reiner
Journal:  J Immunol       Date:  2011-12-02       Impact factor: 5.422

2.  Glycoprotein 96 perpetuates the persistent inflammation of rheumatoid arthritis.

Authors:  Qi-Quan Huang; Renee E Koessler; Robert Birkett; Andrea Dorfleutner; Harris Perlman; G Kenneth Haines; Christian Stehlik; Christopher V Nicchitta; Richard M Pope
Journal:  Arthritis Rheum       Date:  2012-11

3.  Deficiency in TLR2 but not in TLR4 impairs dendritic cells derived IL-10 responses to schistosome antigens.

Authors:  Y Gao; M Zhang; L Chen; M Hou; M Ji; G Wu
Journal:  Cell Immunol       Date:  2011-10-15       Impact factor: 4.868

4.  IL-10 modulates formation of osteoclasts in murine hemopoietic cultures.

Authors:  J M Owens; A C Gallagher; T J Chambers
Journal:  J Immunol       Date:  1996-07-15       Impact factor: 5.422

5.  Fcγ receptor profile of monocytes and macrophages from rheumatoid arthritis patients and their response to immune complexes formed with autoantibodies to citrullinated proteins.

Authors:  Lætitia Laurent; Cyril Clavel; Olivia Lemaire; Florence Anquetil; Martin Cornillet; Laurent Zabraniecki; Leonor Nogueira; Bernard Fournié; Guy Serre; Mireille Sebbag
Journal:  Ann Rheum Dis       Date:  2011-03-15       Impact factor: 19.103

6.  SNAPIN: an endogenous Toll-like receptor ligand in rheumatoid arthritis.

Authors:  Bo Shi; QiQuan Huang; Paul Peter Tak; Margriet J Vervoordeldonk; Chiang-Ching Huang; Andrea Dorfleutner; Christian Stehlik; Richard M Pope
Journal:  Ann Rheum Dis       Date:  2012-04-20       Impact factor: 19.103

7.  Staging the initiation of autoantibody-induced arthritis: a critical role for immune complexes.

Authors:  Brian T Wipke; Zheng Wang; Wouter Nagengast; David E Reichert; Paul M Allen
Journal:  J Immunol       Date:  2004-06-15       Impact factor: 5.422

8.  Elevated interleukin-10 levels in patients with rheumatoid arthritis.

Authors:  J J Cush; J B Splawski; R Thomas; J E McFarlin; H Schulze-Koops; L S Davis; K Fujita; P E Lipsky
Journal:  Arthritis Rheum       Date:  1995-01

9.  Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study.

Authors:  Paul Emery; Tore K Kvien; Bernard Combe; Bruce Freundlich; Deborah Robertson; Tahmina Ferdousi; Eustratios Bananis; Ronald Pedersen; Andrew S Koenig
Journal:  Ann Rheum Dis       Date:  2012-03-08       Impact factor: 19.103

10.  Immunoregulatory role of interleukin 10 in rheumatoid arthritis.

Authors:  P D Katsikis; C Q Chu; F M Brennan; R N Maini; M Feldmann
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

View more
  9 in total

1.  Deletion of calponin 2 in macrophages attenuates the severity of inflammatory arthritis in mice.

Authors:  Qi-Quan Huang; M Moazzem Hossain; Wen Sun; Lianping Xing; Richard M Pope; J-P Jin
Journal:  Am J Physiol Cell Physiol       Date:  2016-08-03       Impact factor: 4.249

2.  Apolipoprotein a-I at the interface of vascular inflammation and arthritis.

Authors:  Robert Terkeltaub
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-03       Impact factor: 8.311

3.  Pristimerin, a naturally occurring triterpenoid, protects against autoimmune arthritis by modulating the cellular and soluble immune mediators of inflammation and tissue damage.

Authors:  Li Tong; Siddaraju M Nanjundaiah; Shivaprasad H Venkatesha; Brian Astry; Hua Yu; Kamal D Moudgil
Journal:  Clin Immunol       Date:  2014-10-13       Impact factor: 3.969

4.  Inhibition of fucosylation reshapes inflammatory macrophages and suppresses type II collagen-induced arthritis.

Authors:  Jun Li; Hui-Chen Hsu; Yana Ding; Hao Li; Qi Wu; PingAr Yang; Bao Luo; Amber L Rowse; David M Spalding; S Louis Bridges; John D Mountz
Journal:  Arthritis Rheumatol       Date:  2014-09       Impact factor: 10.995

5.  Toll-like receptor-mediated IRE1α activation as a therapeutic target for inflammatory arthritis.

Authors:  Quan Qiu; Ze Zheng; Lin Chang; Yuan-Si Zhao; Can Tan; Aditya Dandekar; Zheng Zhang; Zhenghong Lin; Ming Gui; Xiu Li; Tongshuai Zhang; Qingfei Kong; Hulun Li; Sha Chen; An Chen; Randal J Kaufman; Wei-Lei Yang; Hui-Kuan Lin; Donna Zhang; Harris Perlman; Edward Thorp; Kezhong Zhang; Deyu Fang
Journal:  EMBO J       Date:  2013-08-13       Impact factor: 11.598

6.  Transcriptional Profiling of Synovial Macrophages Using Minimally Invasive Ultrasound-Guided Synovial Biopsies in Rheumatoid Arthritis.

Authors:  Arthur M Mandelin; Philip J Homan; Alexander M Shaffer; Carla M Cuda; Salina T Dominguez; Emily Bacalao; Mary Carns; Monique Hinchcliff; Jungwha Lee; Kathleen Aren; Anjali Thakrar; Anna B Montgomery; S Louis Bridges; Joan M Bathon; John P Atkinson; David A Fox; Eric L Matteson; Christopher D Buckley; Costantino Pitzalis; Deborah Parks; Laura B Hughes; Laura Geraldino-Pardilla; Robert Ike; Kristine Phillips; Kerry Wright; Andrew Filer; Stephen Kelly; Eric M Ruderman; Vince Morgan; Hiam Abdala-Valencia; Alexander V Misharin; G Scott Budinger; Elizabeth T Bartom; Richard M Pope; Harris Perlman; Deborah R Winter
Journal:  Arthritis Rheumatol       Date:  2018-05-03       Impact factor: 10.995

7.  CD11c-mediated deletion of Flip promotes autoreactivity and inflammatory arthritis.

Authors:  Qi-Quan Huang; Harris Perlman; Robert Birkett; Renee Doyle; Deyu Fang; G Kenneth Haines; William Robinson; Syamal Datta; Zan Huang; Quan-Zhen Li; Hyewon Phee; Richard M Pope
Journal:  Nat Commun       Date:  2015-05-12       Impact factor: 14.919

8.  Lactobacillus murinus alleviate intestinal ischemia/reperfusion injury through promoting the release of interleukin-10 from M2 macrophages via Toll-like receptor 2 signaling.

Authors:  Jingjuan Hu; Fan Deng; Bingcheng Zhao; Zebin Lin; Qishun Sun; Xiao Yang; Mei Wu; Shida Qiu; Yu Chen; Zhengzheng Yan; Sidan Luo; Jin Zhao; Weifeng Liu; Cai Li; Ke Xuan Liu
Journal:  Microbiome       Date:  2022-03-03       Impact factor: 14.650

Review 9.  Toll-like Receptor 2 in Autoimmune Inflammation.

Authors:  Kathryne E Marks; Kaylin Cho; Courtney Stickling; Joseph M Reynolds
Journal:  Immune Netw       Date:  2021-06-25       Impact factor: 6.303

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.